Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPI-28592 in Advanced Solid Tumors
NCT05302843Phase 1Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Mar 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BPI-28592 in solid tumor (advanced stage), sponsored by Betta Pharmaceuticals. Primary endpoints: Characterize the safety and tolerability of BPI-28592 at 20 months and Recommended Phase II Dose at 20 months. Status: unknown.
02
Drugs
BPI-28592
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05302843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05302843.